Overview

Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

Status:
Terminated

Trial end date:
2020-05-08

Target enrollment:

Participant gender:

Summary

Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alström Syndrome who have completed a preceding ProMetic-sponsored Alström Syndrome study with PBI-4050.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Liminal BioSciences Ltd.
ProMetic BioSciences Inc.